RecruitingNot ApplicableNCT05989763

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

Sponsor

The University of Texas Health Science Center, Houston

Enrollment

60 participants

Start Date

Feb 17, 2024

Study Type

INTERVENTIONAL

Conditions

Constipation Autonomic Dysfunction Systemic Sclerosis Gastrointestinal Motility Disorder

Summary

The purpose of this study is to determine whether transcutaneous electrical acustimulation (TEA) alters systemic sclerosis (SSc)-related colonic and anorectal physiology by enhancing autonomic nervous system (ANS) function. The study will examine the effects of TEA on slow colonic transit (SCT) and rectal hyposensitivity (RH), to examine whether TEA improves autonomic dysfunction and modulates inflammatory pathways.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Sham-TEA and a medical device called Transcutaneous Electrical Acustimulation (TEA) for people with autonomic dysfunction, constipation, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscutaneous Electrical Acustimulation (TEA)

TEA will then be administrated for 1 hour twice daily for a period of 4 weeks

DEVICESham-TEA

Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks

Locations(1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05989763

Related Trials

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT0708510414 locations

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT0692554214 locations

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

NCT0754577270 locations

Balloon Inflation in Biofeedback

NCT077055421 location

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

NCT068279771 location